What is Spectral AI?
Spectral AI is at the forefront of the digital health revolution, specializing in predictive AI solutions that address the complexities of wound care. Its flagship innovation, the DeepView System, is engineered to provide clinicians with immediate, data-backed insights into the healing potential of burn wounds. By Seeing the Unknown, the company seeks to replace subjective clinical observation with precise, objective metrics, thereby facilitating faster and more accurate treatment interventions. This technological shift is poised to disrupt traditional wound care protocols, offering a scalable solution that aligns with the industry's broader transition toward value-based care models.
How much funding has Spectral AI raised?
Spectral AI has raised a total of $104M across 9 funding rounds:
Debt
$350K
Multiple Rounds
$55.4M
Other Financing Round
$8.2M
Other Financing Round
$12.5M
Other Financing Round
$5M
Debt
$15M
Stock/Share Issuance
$7.6M
Debt (2020): $350K with participation from PPP
Other Financing Round (2021): $20.6M led by Biomedical Advanced Research and Development Authority
Stock Issuance/Offering (2021): $16M, investors not publicly disclosed
Other Financing Round (2021): $18.8M featuring US Biomedical Advanced Research and Development Authority
Other Financing Round (2022): $8.2M, investors not publicly disclosed
Other Financing Round (2024): $12.5M, investors not publicly disclosed
Other Financing Round (2024): $5M, investors not publicly disclosed
Debt (2025): $15M supported by AVENUE VENTURE OPPORTUNITIES FUND, LP, as Administrative Agent
Stock/Share Issuance (2025): $7.6M, investors not publicly disclosed
Key Investors in Spectral AI
AVENUE VENTURE OPPORTUNITIES FUND, LP
A specialized investment firm operating within the banking sector, focused on providing strategic debt and venture capital to high-growth enterprises.
Biomedical Advanced Research and Development Authority
A federal agency dedicated to the development and procurement of medical countermeasures to address public health emergencies and advanced medical technologies.
PPP
Public-Private Partnership
What's next for Spectral AI?
With the recent influx of capital, Spectral AI is well-positioned to accelerate the commercialization and clinical integration of the DeepView System. The company's strategic roadmap likely involves expanding its diagnostic algorithms to cover a broader spectrum of wound types, thereby increasing its total addressable market. Furthermore, the continued support from institutional and government-backed entities suggests a focus on regulatory milestones and large-scale clinical validation. As the company moves into this next phase of growth, the emphasis will remain on demonstrating the economic and clinical efficacy of its platform to healthcare providers and payers, ultimately aiming to establish the DeepView System as a standard-of-care diagnostic tool in modern medical facilities.
See full Spectral AI company page
